Pevion Biotech hires new ceo

Also secures CHF10m of financing

Pevion Biotech, a vaccine developer based in Berne, Switzerland, has appointed Evert Kueppers as chief executive, succeeding Thomas Stauffer.

Prior to joining Pevion, Kueppers was ceo of Pieris, a Munich-based biotechnology company, which he successfully restructured and refinanced, raising a total US$45m. Before joining the biotech industry, he spent several years in the International Operations of BASF Pharma (now Abbott Labs) and was a management consultant with the global healthcare team of AT Kearney in London.

The company has also secured further financing of CHF10m from its existing investors, BZ Bank, BB Biotech Ventures and Core Capital.

Pevion says it plans to raise additional financing over the next 12 months to broaden its pipeline.

‘Pevion has reached an important stage in its development as its candidate products reach for critical milestones. This financing commitment should take the company a long way towards achieving further product validation,’ said Joseph Manko of BZ Bank and member of the Board of Directors.

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Manufacturing

Thermo Fisher Scientific doubles down on investment in Asia

New and expanded Bioprocess Design Centres will provide local expertise, advanced technologies and tailored support for biopharma innovators throughout the region
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling

New X and S Series models offer high performance with reduced environmental impact
Finance

EIB and Angelini Ventures launch €150m fund to boost European biotech, medtech and digital health startups

The EIB and Angelini Ventures will co-invest €150 million to scale innovative European healthtech companies. The deal marks the EIB’s first partnership with a corporate venture capital fund in the healthcare sector
Finance

Fresh capital flows into neurodegeneration, cancer and vascular-access developers

A string of funding rounds and strategic financing deals across Europe’s life-sciences sector is breathing new life into companies working on high-need treatments — from neurodegeneration to cancer and dialysis access
Finance

Budget 2025: EY comments on the industrial impact of the Autumn Budget

Mark Minihane, UK&I Industrials and Energy Tax Leader for EY, comments on the industrial implications of the Chancellor’s Autumn Budget
Subscribe now